{"id":37755,"date":"2025-11-04T20:40:40","date_gmt":"2025-11-04T13:40:40","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=37755"},"modified":"2025-11-04T20:40:40","modified_gmt":"2025-11-04T13:40:40","slug":"grit-biotherapeutics-invited-to-deliver-oral-presentation-at-ash-2025-on-breakthrough-in-vivo-car-t-therapy-gt801","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=37755","title":{"rendered":"Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

BEIJING<\/span><\/span>, Nov. 4, 2025<\/span><\/span> \/PRNewswire\/ — Grit\u00a0Biotherapeutics Co., Ltd. (“Grit Bio<\/span>“), a leading clinical-stage biopharmaceutical company pioneering next-generation immunotherapies, today<\/span> announced that its groundbreaking GT801 in vivo CAR-T program has been selected for an oral presentation at the upcoming 67th American Society of Hematology (ASH) Annual Meeting, to be held December 6\u20139, 2025, in Orlando, Florida<\/span>, USA.<\/p>\n

\n<\/div>\n

The abstract, titled “Precision In Vivo CAR-T Generation via CLAMP-Enabled mRNA Delivery: Toward Scalable and Translatable Cell Therapy,” was accepted in the CAR-T Cell Therapies: Basic and Translational session. The presentation will be delivered by Professor Pin Wang, Chief Scientific Officer of Grit Biotherapeutics, on Saturday<\/span>, December 6<\/span>, 9:30\u20139:45 AM (local time) at the OCCC \u2013 Sunburst Room (W340).<\/p>\n

GT801 is an innovative anti-CD19 in vivo CAR-T candidate developed using T-cell-targeted lipid nanoparticles (T-LNPs) encapsulating optimized mRNA. Grit Bio<\/span> leveraged the proprietary CLAMP (Controllable Ligand Attachment Modification and Purification) technology to achieve site-specific antibody conjugation and precise ligand density control. This approach allows selective T-cell targeting, minimal off-target uptake, and robust, durable CAR expression following systemic administration.<\/p>\n

In preclinical studies, GT801 demonstrated:<\/p>\n

    \n
  1. >95% B-cell clearance in humanized\u00a0PBMC mouse models at doses as low as 0.01 mg\/kg;\n<\/li>\n
  2. >80% CAR expression across tissue-resident T cells with <1% off-target delivery to myeloid and hepatic cells;\n<\/li>\n
  3. >30-fold in\u00a0vivo expansion of CAR-T cells with minimal cytokine release (IL-6, TNF-\u03b1), supporting the safety and feasibility of repeat dosing.<\/li>\n<\/ol>\n

    Preliminary clinical data further validate efficient CAR expression, deep B-cell depletion, and repeat-dose tolerability, highlighting GT801’s strong potential as a scalable, off-the-shelf immunotherapy candidate.<\/p>\n

    “The invitation to present at ASH 2025 highlights international recognition of Grit Bio’s<\/span> leadership in advancing in vivo CAR-T innovation,” said Dr. Yarong Liu, Chairman and CEO of Grit Biotherapeutics. “Our GT801 platform represents a paradigm shift in cell therapy\u2014transforming complex ex vivo manufacturing into a simple, repeatable, and scalable in vivo process. We are eager to share our latest clinical data and explore global partnerships that accelerate the translation of this breakthrough technology to patients worldwide.”<\/p>\n

    About Grit Biotherapeutics<\/b><\/p>\n

    Founded in 2019, Grit Biotherapeutics is an innovation-driven, late-stage biopharmaceutical company pioneering next-generation immunotherapies for patients with cancer and autoimmune diseases worldwide. The company’s R&D focuses on TIL-based therapies and in vivo\/off-the-shelf cell therapies for solid tumors and hematologic malignancies. Grit’s lead product GT101, the first TIL therapy approved for clinical trials in China<\/span>, is currently in Phase II pivotal studies. The company’s GT201, the world’s first membrane-bound IL-15 complex\u2013engineered TIL product, has received IND clearance in China<\/span> and the U.S.<\/p>\n

    Media Contact:<\/b><\/p>\n

    Grit Biotherapeutics Co., Ltd.
    Email: BD@grit-bio.com<\/a>
    Website:     www.grit-bio.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

    <\/p>\n\n\n\n
    \"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    BEIJING<\/span><\/span>, Nov. 4, 2025<\/span><\/span> \/PRNewswire\/ — Grit\u00a0Biotherapeutics Co., Ltd. (“Grit Bio<\/span>“), a leading clinical-stage biopharmaceutical company pioneering next-generation immunotherapies, today<\/span> announced that its groundbreaking GT801 in vivo CAR-T program has been selected for an oral presentation at the upcoming 67th American Society of Hematology (ASH) Annual Meeting, to be held December 6\u20139, 2025, in Orlando, Florida<\/span>, USA.<\/p>\n

    \n<\/div>\n

    The abstract, titled “Precision In Vivo CAR-T Generation via CLAMP-Enabled mRNA Delivery: Toward Scalable and Translatable Cell Therapy,” was accepted in the CAR-T Cell Therapies: Basic and Translational session. The presentation will be delivered by Professor Pin Wang, Chief Scientific Officer of Grit Biotherapeutics, on Saturday<\/span>, December 6<\/span>, 9:30\u20139:45 AM (local time) at the OCCC \u2013 Sunburst Room (W340).<\/p>\n

    GT801 is an innovative anti-CD19 in vivo CAR-T candidate developed using T-cell-targeted lipid nanoparticles (T-LNPs) encapsulating optimized mRNA. Grit Bio<\/span> leveraged the proprietary CLAMP (Controllable Ligand Attachment Modification and Purification) technology to achieve site-specific antibody conjugation and precise ligand density control. This approach allows selective T-cell targeting, minimal off-target uptake, and robust, durable CAR expression following systemic administration.<\/p>\n

    In preclinical studies, GT801 demonstrated:<\/p>\n

      \n
    1. >95% B-cell clearance in humanized\u00a0PBMC mouse models at doses as low as 0.01 mg\/kg;\n<\/li>\n
    2. >80% CAR expression across tissue-resident T cells with <1% off-target delivery to myeloid and hepatic cells;\n<\/li>\n
    3. >30-fold in\u00a0vivo expansion of CAR-T cells with minimal cytokine release (IL-6, TNF-\u03b1), supporting the safety and feasibility of repeat dosing.<\/li>\n<\/ol>\n

      Preliminary clinical data further validate efficient CAR expression, deep B-cell depletion, and repeat-dose tolerability, highlighting GT801’s strong potential as a scalable, off-the-shelf immunotherapy candidate.<\/p>\n

      “The invitation to present at ASH 2025 highlights international recognition of Grit Bio’s<\/span> leadership in advancing in vivo CAR-T innovation,” said Dr. Yarong Liu, Chairman and CEO of Grit Biotherapeutics. “Our GT801 platform represents a paradigm shift in cell therapy\u2014transforming complex ex vivo manufacturing into a simple, repeatable, and scalable in vivo process. We are eager to share our latest clinical data and explore global partnerships that accelerate the translation of this breakthrough technology to patients worldwide.”<\/p>\n

      About Grit Biotherapeutics<\/b><\/p>\n

      Founded in 2019, Grit Biotherapeutics is an innovation-driven, late-stage biopharmaceutical company pioneering next-generation immunotherapies for patients with cancer and autoimmune diseases worldwide. The company’s R&D focuses on TIL-based therapies and in vivo\/off-the-shelf cell therapies for solid tumors and hematologic malignancies. Grit’s lead product GT101, the first TIL therapy approved for clinical trials in China<\/span>, is currently in Phase II pivotal studies. The company’s GT201, the world’s first membrane-bound IL-15 complex\u2013engineered TIL product, has received IND clearance in China<\/span> and the U.S.<\/p>\n

      Media Contact:<\/b><\/p>\n

      Grit Biotherapeutics Co., Ltd.
      Email: BD@grit-bio.com<\/a>
      Website:       www.grit-bio.com<\/a><\/p>\n

      <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-37755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/37755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37755"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/37755\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}